We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

NiKem Research Receives Approval as a “Crédit d’Impôt Recherche” Certified Company from the French Ministry of Research

Read time: Less than a minute

NiKem Research Srl, an international service provider in the field of Drug Discovery based in Italy, had announced that the French Ministry of Research (FMR) has accepted the company’s request to be included in the list of FMR approved contract research organizations (CROs) carrying out R&D activities for French private companies.

This approval, which is valid for the three year period between 2008 and 2010 and could be renewed afterwards, entitles and will entitle any French private company to claim significant tax credit (“Crédit d’Impôt Recherche”, C.I.R.) for R&D activities executed by NiKem Research on their behalf in the above mentioned time period.

NiKem believes that its C.I.R. certification may now allow a further expansion of business relationships with French companies, and is committed to provide an extremely cost-effective support to any interested French partner.

Giuseppe Giardina, CEO & Managing Director of NiKem, said: "The approval as a C.I.R. certified company by the French Ministry of Research is an important step forward for NiKem. We believe that our already significant business volume with French pharmaceutical and, most importantly, biotech companies will grow: in fact, our high quality standards are now combined with competitive prices and tax credit options. Thus, we expect to at least double our revenues in France in the next three years."